A global Phase IIb study of linerixibat for the treatment of cholestatic ...

Linerixibat may provide an effective treatment option for cholestatic pruritus in patients with primary biliary cholangitis.

GSK presents Phase 2b data on linerixibat for the treatment of ...

Issued: London, UK. Data from the GLIMMER study presented as a late-breaking session at The Liver Meeting® 2020; First study to leverage the ...

Linerixibat may provide an effective treatment option for cholestatic pruritus in patients with primary biliary cholangitis. Clinical Trial ...

Japanese subgroup analysis of GLIMMER: A global Phase IIb study ...

Linerixibat may provide an effective treatment option for cholestatic pruritus in patients with primary biliary cholangitis.

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

Linerixibat has the potential to treat cholestatic pruritus in patients with PBC, addressing a major unmet need for this patient population. Pruritus (itch) ...

A global Phase IIb study of linerixibat for the treatment of cholestatic ...

GLIMMER was a multicenter, double-blind, randomized, placebo-controlled, Phase IIb study evaluating linerixibat for the treatment of pruritus in patients with ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

GLIMMER assessed dose-response, efficacy, and safety of linerixibat, an ileal bile acid transporter inhibitor in development for cholestatic pruritus.

Investigation of linerixibat 40 mg BID for cholestatic pruritus of ...

GLIMMER (NCT02966834) was a double-blind, randomised, placebo-controlled, Phase 2b dose-response study of linerixibat for patients with PBC and ...

Press release | GSK

Additionally, data from the GLIMMER phase IIb trial validates the worst itch numerical rating scale (NRS) and ... 3 GLISTEN (Global Linerixibat ...

Linerixibat - an overview | ScienceDirect Topics

Currently, A3309 completed Phase IIb clinical trial (ClinicalTrials.gov Identifier: NCT01007123) in the treatment of constipation and CC and showed the ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

Post hoc analysis of change from baseline in monthly itch score over the treatment period (Phase 3 endpoint) showed significant differences ...

NCT04950127 - ClinicalTrials.gov

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of ...

Linerixibat has the potential to treat cholestatic pruritus in patients with PBC, addressing a major unmet need for this patient population ...

linerixibat (GSK2330672) News - LARVOL Sigma

... Phase 3 GLISTEN trial (NCT04950127) of linerixibat for pruritus treatment in PBC. ... P2b data, Journal: Japanese subgroup analysis of GLIMMER: A global Phase 2b ...

Health Technology Briefing February 2023

3. GlaxoSmithKline. GSK presents Phase 2b data on linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). 2020. Available ...

Linerixibat dose-response analysis of C4 concentrations as a ...

NCT04950127) for the treatment of cholestatic ... sample) over time for linerixibat dosing regimens assessed in the Phase 2b study.

Relationship between pruritus and sleep in participants with primary ...

The first was a Phase 2b study where 4 out of 10 patients treated ... cholestatic liver disease: phase 2 study. Clin Res Hepatol ...

Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and ...

In a Phase 2a, double-blind, randomised, placebo-controlled, crossover trial in adults with PBC, 14 days of linerixibat treatment led to ...

linerixibat (GSK2330672) / GSK - LARVOL DELTA

... GLOBAL LINERIXIBAT ITCH STUDY OF EFFICACY AND ... Phase 2b trial of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis ...

Treating Itch in Primary Biliary Cholangitis: A GLIMMER of Hope ...

4. Levy, C. ∙ Kendrick, S. ∙ Bowlus, C.L. ... GLIMMER: a randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis ...